FOLH1 and neoplasm: The resulting efficacy of [177Lu]Lu-PSMA-ALB-56 for the treatment of PSMA-positive PC-3 PIP tumor-bearing mice was significantly improved as compared with that of the same activity of [177Lu]Lu-PSMA-617 [25].